Payment overview · 2025
General Payments
$694.83
20 reported records · 6 companies
Healthcare provider profile · identity verified
John David Venuti, DO
Allopathic & Osteopathic Physicians|Family Medicine · TURNERSVILLE, NJ · NPI 1487668398
Verified facts
What the public records show
CMS Open Payments records show John David Venuti, DO received $694.83 in general payments during 2025 across 20 reported records.
ZOLL Medical Corporation accounted for 48.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ZOLL Medical Corporation | Unresolved — no canonical attribution shown | $338.33 | 48.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $172.78 | 24.9% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $122.10 | 17.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.06 | 4.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.97 | 2.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.59 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $356.50 | 19 |
| Consulting Fee | $338.33 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Defibrillator Normalized: defibrillator |
Device | ZOLL Medical Corporation | $338.33 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $172.78 | 15 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $122.10 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.06 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 808 | 262 |
| Levothyroxine Sodium | Levothyroxine Sodium | 688 | 207 |
| Amlodipine Besylate | Amlodipine Besylate | 647 | 212 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 459 | 148 |
| Losartan Potassium | Losartan Potassium | 405 | 130 |
| Omeprazole | Omeprazole | 375 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 312 | 96 |
| Escitalopram Oxalate | Escitalopram Oxalate | 287 | 86 |
| Metformin Hcl | Metformin Hcl | 277 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 271 | 87 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 264 | 85 |
| Simvastatin | Simvastatin | 260 | 72 |
| Montelukast Sodium | Montelukast Sodium | 259 | 81 |
| Quetiapine Fumarate | Quetiapine Fumarate | 243 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 227 | 81 |
| Lisinopril | Lisinopril | 225 | 82 |
| Gabapentin | Gabapentin | 186 | 59 |
| Ozempic | Semaglutide | 179 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 59 |
| Ezetimibe | Ezetimibe | 168 | 56 |
| Carvedilol | Carvedilol | 157 | 49 |
| Furosemide | Furosemide | 151 | 58 |
| Trazodone Hcl | Trazodone Hcl | 147 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 40 |
| Sertraline Hcl | Sertraline Hcl | 117 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 39 |
| Potassium Chloride | Potassium Chloride | 105 | 41 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 104 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 46 |
| Tramadol Hcl | Tramadol Hcl | 96 | 34 |
| Eliquis | Apixaban | 95 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 33 |
| Synthroid | Levothyroxine Sodium | 84 | 24 |
| Allopurinol | Allopurinol | 80 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 31 |
| Alprazolam | Alprazolam | 74 | 33 |
| Metformin Hcl Er | Metformin Hcl | 69 | 23 |
| Ibuprofen | Ibuprofen | 68 | 30 |
| Fenofibrate | Fenofibrate Nanocrystallized | 66 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 16 |
| Valsartan | Valsartan | 65 | 25 |
| Methylprednisolone | Methylprednisolone | 64 | 59 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 52 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 61 | 46 |
| Famotidine | Famotidine | 61 | 22 |
| Atenolol | Atenolol | 60 | 18 |
| Bupropion Xl | Bupropion Hcl | 60 | 21 |
| Jardiance | Empagliflozin | 60 | 19 |
| Celecoxib | Celecoxib | 57 | 22 |
| Januvia | Sitagliptin Phosphate | 57 | 14 |
| Xarelto | Rivaroxaban | 57 | 12 |
| Finasteride | Finasteride | 56 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | 16 |
| Meloxicam | Meloxicam | 55 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 55 | 17 |
| Glipizide Er | Glipizide | 51 | 13 |
| Azithromycin | Azithromycin | 50 | 49 |
| Repatha Sureclick | Evolocumab | 50 | suppressed |
| Mirtazapine | Mirtazapine | 49 | 14 |
| Naproxen | Naproxen | 49 | 16 |
| Donepezil Hcl | Donepezil Hcl | 48 | 21 |
| Pregabalin | Pregabalin | 48 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | 14 |
| Glimepiride | Glimepiride | 46 | 19 |
| Clonazepam | Clonazepam | 45 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 16 |
| Valacyclovir | Valacyclovir Hcl | 45 | 21 |
| Linzess | Linaclotide | 44 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 44 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 14 |
| Alendronate Sodium | Alendronate Sodium | 43 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 15 |
| Lorazepam | Lorazepam | 43 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | 11 |
| Fluconazole | Fluconazole | 42 | 33 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 41 | suppressed |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 40 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 13 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Spironolactone | Spironolactone | 39 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | 12 |
| Glipizide | Glipizide | 37 | 12 |
| Ramipril | Ramipril | 37 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | 11 |
| Tradjenta | Linagliptin | 36 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 18 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 12 |
| Memantine Hcl | Memantine Hcl | 32 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | 11 |
| Farxiga | Dapagliflozin Propanediol | 30 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 18 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 20 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 19 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 18 | suppressed |
| Klor-Con M10 | Potassium Chloride | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Desmopressin Acetate | Desmopressin (Nonrefrigerated) | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 12 |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $694.83 · 20 records | ZOLL Medical Corporation | Defibrillator, OTEZLA, REPATHA, REXULTI, The Cologuard Plus Collection Kit, VRAYLAR, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error